Journal
CLINICAL LUNG CANCER
Volume 23, Issue 2, Pages E116-E117Publisher
CIG MEDIA GROUP, LP
DOI: 10.1016/j.cllc.2021.12.003
Keywords
Immune checkpoint inhibitors; Immune-related pneumonitis; Interstitial lung disease; Lipid-laden macrophage; Respiratory failure
Categories
Ask authors/readers for more resources
Diagnosing newly emerged abnormal lung shadows during treatment with immune checkpoint inhibitors can be challenging. Clinicians should be aware of this rare but severe phenomenon in patients undergoing immune checkpoint inhibitor therapy.
It is often challenging to diagnose newly emerged abnormal lung shadows during treatment with immune checkpoint inhibitors. We report an autopsy case of a patient who developed lipoid pneumonia after a single dose of pembrolizumab. Clinicians will bear in mind this rare but severe phenomenon in patients undergoing immune checkpoint inhibitor therapy. (C) 2021 Elsevier Inc. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available